RxDoctor Payments Data

Diana Wemhoff

Primary Care · Moberly, MONPI 1114029451

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,131 and has fallen 98.6% since, to $16 in 2024.

$2,443in general payments, 2019–2025

Across 161 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$346
  • AbbVie$326
  • Lilly USA, LLC$247
  • Amgen$182
  • Novo Nordisk$166
  • Takeda Pharmaceuticals U.S.A., Inc.$155
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,443 in reported general payments places this provider in the 85th percentile of 106 primary care providers in Missouri.

See all primary care providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,510
FarxigaDapagliflozin Propanediol11$6,654
VascepaIcosapent Ethyl24$4,158
JanuviaSitagliptin Phosphate12$3,439
Omeprazole47$542
Atorvastatin Calcium72$538
Levothyroxine Sodium50$343
Lisinopril41$280
Oxybutynin Chloride12$241
Tizanidine Hcl15$233
Donepezil Hcl24$225
Hydralazine Hcl12$204
Glipizide13$203
Isosorbide Mononitrate ErIsosorbide Mononitrate12$185
Carvedilol12$181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$50$7,51011 claims
AstraZenecaFarxiga$346$6,65411 claims
MerckJanuvia$68$3,43912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 106 primary care providers in Missouri.

Other primary care in Moberly

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →